Medicus Pharma Ltd. Announces Expansion of SKNJCT-003 Clinical Trial and Plans Acquisition of UK-Based Antev Ltd

Reuters

2025/07/21

<a href="https://laohu8.com/S/MDCX">Medicus Pharma Ltd.</a> Announces Expansion of SKNJCT-003 Clinical Trial and Plans Acquisition of UK-Based Antev Ltd

Medicus Pharma Ltd. has announced an expansion of its Phase 2 clinical study for SKNJCT-003, which began randomizing patients in August 2024 across nine clinical sites in the United States. Following a positively trending interim analysis in March 2025, showing over 60% clinical clearance, the investigational review board has increased the number of study participants to 90 subjects. The interim results are preliminary and may not necessarily reflect the final study outcomes. Additionally, the company is expanding its clinical trial sites into Europe. The lead asset, SkinJect Inc., focuses on a novel treatment for non-melanoma skin cancer using a patented dissolvable doxorubicin-containing microneedle array. Furthermore, Medicus Pharma Ltd. will present at the BTIG Virtual Biotech Conference 2025, where Dr. Raza Bokhari, Executive Chairman and CEO, will participate in a fireside chat on July 30, 2025. The chat will be livestreamed for registered investors, and a recording will be available for conference attendees.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicus Pharma Ltd. published the original content used to generate this news brief via Newsfile (Ref. ID: 259382) on July 21, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2553479621"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2553479621\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2553479621?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-21 19:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2553479621","market":"nz","top_or_hot":-1,"title":"Medicus Pharma Ltd. Announces Expansion of SKNJCT-003 Clinical Trial and Plans Acquisition of UK-Based Antev Ltd","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/MDCX\">Medicus Pharma Ltd.</a> Announces Expansion of SKNJCT-003 Clinical Trial and Plans Acquisition of UK-Based Antev Ltd\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/MDPLD\">Medicus Pharma</a> Ltd. has announced an expansion of its Phase 2 clinical study for SKNJCT-003, which began randomizing patients in August 2024 across nine clinical sites in the United States. Following a positively trending interim analysis in March 2025, showing over 60% clinical clearance, the investigational review board has increased the number of study participants to 90 subjects. The interim results are preliminary and may not necessarily reflect the final study outcomes. Additionally, the company is expanding its clinical trial sites into Europe. The lead asset, SkinJect Inc., focuses on a novel treatment for non-melanoma skin cancer using a patented dissolvable doxorubicin-containing microneedle array. Furthermore, <a href=\"https://laohu8.com/S/MDPLF\">Medicus Pharma</a> Ltd. will present at the BTIG Virtual Biotech Conference 2025, where Dr. Raza Bokhari, Executive Chairman and CEO, will participate in a fireside chat on July 30, 2025. The chat will be livestreamed for registered investors, and a recording will be available for conference attendees.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicus Pharma Ltd. published the original content used to generate this news brief via Newsfile (Ref. ID: 259382) on July 21, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Medicus Pharma Ltd. Announces Expansion of SKNJCT-003 Clinical Trial and Plans Acquisition of UK-Based Antev Ltd</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMedicus Pharma Ltd. Announces Expansion of SKNJCT-003 Clinical Trial and Plans Acquisition of UK-Based Antev Ltd\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-21 19:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/MDCX\">Medicus Pharma Ltd.</a> Announces Expansion of SKNJCT-003 Clinical Trial and Plans Acquisition of UK-Based Antev Ltd\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/MDPLD\">Medicus Pharma</a> Ltd. has announced an expansion of its Phase 2 clinical study for SKNJCT-003, which began randomizing patients in August 2024 across nine clinical sites in the United States. Following a positively trending interim analysis in March 2025, showing over 60% clinical clearance, the investigational review board has increased the number of study participants to 90 subjects. The interim results are preliminary and may not necessarily reflect the final study outcomes. Additionally, the company is expanding its clinical trial sites into Europe. The lead asset, SkinJect Inc., focuses on a novel treatment for non-melanoma skin cancer using a patented dissolvable doxorubicin-containing microneedle array. Furthermore, <a href=\"https://laohu8.com/S/MDPLF\">Medicus Pharma</a> Ltd. will present at the BTIG Virtual Biotech Conference 2025, where Dr. Raza Bokhari, Executive Chairman and CEO, will participate in a fireside chat on July 30, 2025. The chat will be livestreamed for registered investors, and a recording will be available for conference attendees.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicus Pharma Ltd. published the original content used to generate this news brief via Newsfile (Ref. ID: 259382) on July 21, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MDCX","symbol_name":"Medicus Pharma Ltd.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250721:nNDL4Q7Fwv:1","article_id":"2553479621","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2553479621","pubTimestamp":1753097473,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Medicus Pharma Ltd. has announced an expansion of its Phase 2 clinical study for SKNJCT-003, which began randomizing patients in August 2024 across nine clinical sites in the United States. Following a positively trending interim analysis in March 2025, showing over 60% clinical clearance, the investigational review board has increased the number of study participants to 90 subjects. The interim results are preliminary and may not necessarily reflect the final study outcomes. Additionally, the company is expanding its clinical trial sites into Europe. The lead asset, SkinJect Inc., focuses on a novel treatment for non-melanoma skin cancer using a patented dissolvable doxorubicin-containing microneedle array. Furthermore, Medicus Pharma Ltd. will present at the BTIG Virtual Biotech Conference 2025, where Dr. Raza Bokhari, Executive Chairman and CEO, will participate in a fireside chat on July 30, 2025. The chat will be livestreamed for registered investors, and a recording will be avail","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MDCX":"Medicus Pharma Ltd.","BK4139":"生物科技"},"translate_title":"Medicus Pharma Ltd.宣布扩大SKNJCT-003临床试验并计划收购英国Antev Ltd","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MDCX":0.9},"content_text":"Medicus Pharma Ltd. Announces Expansion of SKNJCT-003 Clinical Trial and Plans Acquisition of UK-Based Antev Ltd\n    \n\nMedicus Pharma Ltd. has announced an expansion of its Phase 2 clinical study for SKNJCT-003, which began randomizing patients in August 2024 across nine clinical sites in the United States. Following a positively trending interim analysis in March 2025, showing over 60% clinical clearance, the investigational review board has increased the number of study participants to 90 subjects. The interim results are preliminary and may not necessarily reflect the final study outcomes. Additionally, the company is expanding its clinical trial sites into Europe. The lead asset, SkinJect Inc., focuses on a novel treatment for non-melanoma skin cancer using a patented dissolvable doxorubicin-containing microneedle array. Furthermore, Medicus Pharma Ltd. will present at the BTIG Virtual Biotech Conference 2025, where Dr. Raza Bokhari, Executive Chairman and CEO, will participate in a fireside chat on July 30, 2025. The chat will be livestreamed for registered investors, and a recording will be available for conference attendees.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicus Pharma Ltd. published the original content used to generate this news brief via Newsfile (Ref. ID: 259382) on July 21, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}